BiondVax Pharmaceuticals Ltd. (BVXV)
Price:
1.36 USD
( + 0.01 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)

(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Regeneron Pharmaceuticals, Inc.
VALUE SCORE:
6
2nd position
Genmab A/S
VALUE SCORE:
11
The best
Agios Pharmaceuticals, Inc.
VALUE SCORE:
12
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
No data to display
No data to display
DESCRIPTION
BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.
NEWS

BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd.
globenewswire.com
2023-09-06 06:00:00Scinai Immunotherapeutics to debut tomorrow under Nasdaq ticker symbol “SCNI” Scinai Immunotherapeutics to debut tomorrow under Nasdaq ticker symbol “SCNI”

BiondVax Reports Second Quarter Financial Results and Provides Business Update
globenewswire.com
2023-08-11 09:00:00JERUSALEM, Aug. 11, 2023 (GLOBE NEWSWIRE) -- via IBN - BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announced the publication today of its financial results for the second quarter ended June 30, 2023, and provided a business update.

Nasdaq Grants BiondVax Extension to Regain Compliance with Listing Rules
globenewswire.com
2023-08-01 16:01:00JERUSALEM, Aug. 01, 2023 (GLOBE NEWSWIRE) -- via IBN -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today announced that Nasdaq reviewed BiondVax's multi-faceted plan to regain compliance with Nasdaq's Listing Rule 5550(b) and provided it an extension until October 30, 2023, to demonstrate compliance.

BiondVax to Present at BIO-Europe Spring
globenewswire.com
2023-03-16 13:10:00JERUSALEM, March 16, 2023 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd . (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announces today that its CEO Amir Reichman will be presenting in-person at the 17th annual BIO-Europe Spring taking place March 20–22, 2023, in Basel, Switzerland. The event is expected to bring together over 2,800 executives from biotech, pharma and finance companies to engage in 15,000+ one-to-one meetings.

BiondVax Presenting at BIO CEO & Investor Conference
globenewswire.com
2023-02-02 14:15:00JERUSALEM, Feb. 02, 2023 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd . ( Nasdaq: BVXV ), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announced today that its CEO Amir Reichman will present at the BIO CEO & Investor Conference . The conference is taking place Feb. 6-9, 2023, in New York.

Best Penny Stocks To Buy? 5 To Watch After Big News This Week
pennystocks.com
2023-01-23 09:28:30Penny stocks to watch with news that are turning heads in the stock market this week. The post Best Penny Stocks To Buy?

BiondVax CEO to Present at the January 2023 Biotech Showcase in San Francisco
prnewswire.com
2022-11-21 06:00:00JERUSALEM , Nov. 21, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) ("BiondVax"), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announced today that its CEO Amir Reichman will present at the January 9-11, 2023 Biotech Showcase conference.

BiondVax to present at Recent Advances in Fermentation Technology (RAFT) 14 Conference
prnewswire.com
2022-11-03 11:30:00JERUSALEM , Nov. 3, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) ("BiondVax"), a biotechnology company focused on developing, manufacturing, and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, announced today that Dr. Dalit Weinstein Fischer , BiondVax's Head of Technical R&D, will attend and present at Recent Advances in Fermentation Technology (RAFT) 14, a conference of the Society for Industrial Microbiology and Biotechnology (SIMB) taking place November 6 to 9, 2022 in Orlando, Florida.

BiondVax to Present at LD Micro Investor Conference in Los Angeles
newsfilecorp.com
2022-10-18 07:55:00Jerusalem, Israel--(Newsfile Corp. - October 18, 2022) - BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) ("BiondVax"), a biotechnology company focused on developing, manufacturing, and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, announced today that Joshua Phillipson, BiondVax's Director of Investor Relations, will attend and present at the LD Micro Main Event XV, an investor conference taking place October 25 to 27, 2022 in Los Angeles.

BiondVax to present at LD Micro Investor Conference in Los Angeles
prnewswire.com
2022-10-11 14:00:00JERUSALEM , Oct. 11, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) ("BiondVax"), a biotechnology company focused on developing, manufacturing, and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, announced today that Joshua Phillipson, BiondVax's Director of Investor Relations, will attend and present at the LD Micro Main Event XV, an investor conference taking place October 25 to 27, 2022 in Los Angeles.

BiondVax to Present at H.C. Wainwright 24th Annual Global Investment Conference
prnewswire.com
2022-09-08 09:13:00JERUSALEM , Sept. 8, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd.

BiondVax to Present at this week's Biomed Israel Conference
prnewswire.com
2022-05-09 06:00:00JERUSALEM , May 9, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, today announced that it will present at the 20th Biomed Israel Conference and Exhibition, to be held May 10-12, 2022, in Tel Aviv, Israel.

BiondVax Pharmaceuticals Ltd. (BVXV) CEO Amir Reichman on Q4 2021 Results - Earnings Call Transcript
seekingalpha.com
2022-04-04 15:23:08BiondVax Pharmaceuticals Ltd. (BVXV) CEO Amir Reichman on Q4 2021 Results - Earnings Call Transcript

BiondVax Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
prnewswire.com
2022-03-28 07:00:00JERUSALEM, March 28, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, today published its fourth quarter and full year financial results for the year ended December 31, 2021 and provided a business update.

Why Is BiondVax (BVXV) Stock Up Today?
investorplace.com
2022-03-24 13:15:37BVXV stock is climbing today on news that BiondVax has struck a deal to pursue a range of antibody treatments. Here's what to know.

Here's Why Biondvax Pharmaceuticals Shares Are Rising
benzinga.com
2022-03-24 12:03:16Biondvax Pharmaceuticals Ltd - ADR (NASDAQ: BVXV) shares are trading higher by 32.1% at $1.81 after the company announced it signed a definitive collaboration agreement for the development of a pipeline of innovative nanosized antibody therapies. BiondVax says the company is planning a rapid.
No data to display

BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd.
globenewswire.com
2023-09-06 06:00:00Scinai Immunotherapeutics to debut tomorrow under Nasdaq ticker symbol “SCNI” Scinai Immunotherapeutics to debut tomorrow under Nasdaq ticker symbol “SCNI”

BiondVax Reports Second Quarter Financial Results and Provides Business Update
globenewswire.com
2023-08-11 09:00:00JERUSALEM, Aug. 11, 2023 (GLOBE NEWSWIRE) -- via IBN - BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announced the publication today of its financial results for the second quarter ended June 30, 2023, and provided a business update.

Nasdaq Grants BiondVax Extension to Regain Compliance with Listing Rules
globenewswire.com
2023-08-01 16:01:00JERUSALEM, Aug. 01, 2023 (GLOBE NEWSWIRE) -- via IBN -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today announced that Nasdaq reviewed BiondVax's multi-faceted plan to regain compliance with Nasdaq's Listing Rule 5550(b) and provided it an extension until October 30, 2023, to demonstrate compliance.

BiondVax to Present at BIO-Europe Spring
globenewswire.com
2023-03-16 13:10:00JERUSALEM, March 16, 2023 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd . (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announces today that its CEO Amir Reichman will be presenting in-person at the 17th annual BIO-Europe Spring taking place March 20–22, 2023, in Basel, Switzerland. The event is expected to bring together over 2,800 executives from biotech, pharma and finance companies to engage in 15,000+ one-to-one meetings.

BiondVax Presenting at BIO CEO & Investor Conference
globenewswire.com
2023-02-02 14:15:00JERUSALEM, Feb. 02, 2023 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd . ( Nasdaq: BVXV ), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announced today that its CEO Amir Reichman will present at the BIO CEO & Investor Conference . The conference is taking place Feb. 6-9, 2023, in New York.

Best Penny Stocks To Buy? 5 To Watch After Big News This Week
pennystocks.com
2023-01-23 09:28:30Penny stocks to watch with news that are turning heads in the stock market this week. The post Best Penny Stocks To Buy?

BiondVax CEO to Present at the January 2023 Biotech Showcase in San Francisco
prnewswire.com
2022-11-21 06:00:00JERUSALEM , Nov. 21, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) ("BiondVax"), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announced today that its CEO Amir Reichman will present at the January 9-11, 2023 Biotech Showcase conference.

BiondVax to present at Recent Advances in Fermentation Technology (RAFT) 14 Conference
prnewswire.com
2022-11-03 11:30:00JERUSALEM , Nov. 3, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) ("BiondVax"), a biotechnology company focused on developing, manufacturing, and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, announced today that Dr. Dalit Weinstein Fischer , BiondVax's Head of Technical R&D, will attend and present at Recent Advances in Fermentation Technology (RAFT) 14, a conference of the Society for Industrial Microbiology and Biotechnology (SIMB) taking place November 6 to 9, 2022 in Orlando, Florida.

BiondVax to Present at LD Micro Investor Conference in Los Angeles
newsfilecorp.com
2022-10-18 07:55:00Jerusalem, Israel--(Newsfile Corp. - October 18, 2022) - BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) ("BiondVax"), a biotechnology company focused on developing, manufacturing, and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, announced today that Joshua Phillipson, BiondVax's Director of Investor Relations, will attend and present at the LD Micro Main Event XV, an investor conference taking place October 25 to 27, 2022 in Los Angeles.

BiondVax to present at LD Micro Investor Conference in Los Angeles
prnewswire.com
2022-10-11 14:00:00JERUSALEM , Oct. 11, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) ("BiondVax"), a biotechnology company focused on developing, manufacturing, and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, announced today that Joshua Phillipson, BiondVax's Director of Investor Relations, will attend and present at the LD Micro Main Event XV, an investor conference taking place October 25 to 27, 2022 in Los Angeles.

BiondVax to Present at H.C. Wainwright 24th Annual Global Investment Conference
prnewswire.com
2022-09-08 09:13:00JERUSALEM , Sept. 8, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd.

BiondVax to Present at this week's Biomed Israel Conference
prnewswire.com
2022-05-09 06:00:00JERUSALEM , May 9, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, today announced that it will present at the 20th Biomed Israel Conference and Exhibition, to be held May 10-12, 2022, in Tel Aviv, Israel.

BiondVax Pharmaceuticals Ltd. (BVXV) CEO Amir Reichman on Q4 2021 Results - Earnings Call Transcript
seekingalpha.com
2022-04-04 15:23:08BiondVax Pharmaceuticals Ltd. (BVXV) CEO Amir Reichman on Q4 2021 Results - Earnings Call Transcript

BiondVax Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
prnewswire.com
2022-03-28 07:00:00JERUSALEM, March 28, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, today published its fourth quarter and full year financial results for the year ended December 31, 2021 and provided a business update.

Why Is BiondVax (BVXV) Stock Up Today?
investorplace.com
2022-03-24 13:15:37BVXV stock is climbing today on news that BiondVax has struck a deal to pursue a range of antibody treatments. Here's what to know.

Here's Why Biondvax Pharmaceuticals Shares Are Rising
benzinga.com
2022-03-24 12:03:16Biondvax Pharmaceuticals Ltd - ADR (NASDAQ: BVXV) shares are trading higher by 32.1% at $1.81 after the company announced it signed a definitive collaboration agreement for the development of a pipeline of innovative nanosized antibody therapies. BiondVax says the company is planning a rapid.